Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 17, 2004. The report details a share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 17, 2004, and discloses changes in directors' interests regarding the GlaxoSmithKline Employee Trust.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 430,000 Ordinary shares of 25 pence each.
- Purchase Date: June 16, 2004.
- Purchase Price: 1,148.17 pence per share.
- Treasury Holdings Post-Transaction: 22,129,000 shares.
- Shares in Issue (excluding Treasury): 5,911,465,669 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 430,000 shares, which are now held in Treasury. Additionally, the GlaxoSmithKline Employee Trust transferred 10,489 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 430,000 share repurchase based on the disclosed price of 1,148.17 pence.
- Confirm the updated total share count and Treasury holdings against subsequent filings.
- Review the impact of the 10,489 share transfer from the GSK Trust on employee option plan liabilities.
- Note that this filing does not contain operational or financial performance data for the period.